Lifebank is more than a cord blood and tissue bank, it is part of Celularity Inc., a clinical stage cell therapy company developing and manufacturing allogeneic, placenta derived cellular medicines. This connection provides families not only long term cell storage, but proximity to active translational research and regulated cell therapy manufacturing.

What This Study Looked At

This prospective, randomized, placebo-controlled, double-blind study evaluated whether UCB infusion is safe and associated with improved social and communication abilities in children with autism spectrum disorder (ASD). This study included 180 children with ASD, aged 2-7 years, who received a single intravenous autologous (n = 56) or allogeneic (n = 63) UCB infusion vs placebo (n = 61) and were evaluated at 6 months post infusion.

What The Researchers Found

UCB infusion was safe and well tolerated. Analysis of the entire sample showed no evidence that UCB was associated with improvements in the primary outcome, social communication or the secondary outcomes, autism symptoms. There was also no overall evidence of differential effects by type of UCB infused.

Who appeared to benefit most:

In a subanalysis of children without intellectual disability (ID), allogeneic, but not autologous, UCB was associated with improvement in a larger percentage of children, but the improvement was not significant. Children without ID treated with UCB showed significant improvements in communication skills, and exploratory measures including attention to toys and sustained attention (eye-tracking) and increased alpha and beta electroencephalographic power.

What These Results Mean

Overall, a single infusion of UCB was not associated with improved socialization skills or reduced autism symptoms. More research is warranted to determine whether UCB infusion is an effective treatment for some children with ASD. A Phase II randomized, placebo controlled trial evaluating intravenous umbilical cord blood infusion in young children with ASD found the treatment to be safe but not associated with significant improvement in core autism symptoms overall, though exploratory subgroup analyses suggested potential signals in selected populations (Dawson G et al., J Pediatrics, 2020).

What This Study Looked At

The researchers explored whether umbilical cord tissue cells could be safely given to children with cerebral palsy (CP) and whether this was associated with improvements in movement, daily functioning, and quality of life. The study included 72 children between 4 and 14 years of age with spastic CP. Children were randomly assigned to receive either the cell treatment or a sham (placebo) procedure, and neither families nor doctors knew which treatment a child received. Researchers followed the children for one year, using standardized tests to measure motor skills, muscle stiffness, daily activities, quality of life, and changes seen on brain imaging.

What The Researchers Found

Movement and daily function:
Children who received the umbilical cord tissue–derived cells showed greater improvements in movement abilities, such as sitting, standing, and walking skills, compared with children who did not receive the cells. Improvements were also seen in daily activities, including mobility and self care.

Muscle stiffness:
Children in the treatment group experienced reduced muscle tightness over time, which can make movement more comfortable and functional for some children.

Quality of life:
Parents reported improvements in areas such as communication, participation in activities, and social interaction in children who received the cell treatment compared with those who did not.

Brain imaging:
Advanced MRI scans showed positive changes in brain pathways related to movement in the treated group, suggesting improved organization of important motor connections.

Safety Observations

The treatment was well tolerated. No serious side effects related to the cells were reported during the study. Minor, temporary effects related to the injection procedure were similar between children who received the cells and those who received the sham procedure. Overall, the study did not identify new safety concerns from the use of these cells in this setting.

What These Results Mean

• Treatment with umbilical cord tissue–derived cells may be associated with meaningful improvements in movement, daily function, and certain aspects of quality of life for some children with spastic cerebral palsy.
• This treatment is still considered investigational. The study involved a single dose, a specific group of children, and a limited number of participants.
• These findings help researchers better understand how perinatal cell therapies might work and support continued clinical research, but more studies are needed to determine who may benefit most, and how durable the improvements are.

What This Study Looked At

This study reviewed and analyzed clinical studies evaluating mesenchymal stromal cells (MSCs) as an investigational approach for children with cerebral palsy (CP). The authors conducted a review of the existing clinical literature and included an analysis focusing on changes in gross motor function, measured using standardized tools such as the Gross Motor Function Measure (GMFM).
The review included studies using MSCs derived from various sources, including perinatal tissues, and encompassed different study designs, dosing approaches, routes of administration, and patient populations.

What The Researchers Found

Motor function outcomes:
Across analyzed studies, MSC administration was associated with small improvements in gross motor function compared with baseline or control groups in some trials. The magnitude of improvement varied widely across studies.

Outcomes differed substantially depending on:
• Age of the child
• Severity and type of cerebral palsy
• Cell source and dose
• Timing and route of administration
This variability limited direct comparisons between studies.

Safety Observations

Reported adverse events were generally mild to moderate, and serious adverse events were uncommon. Overall, the available data did not identify new or consistent safety concerns, although study sizes were relatively small.

What These Results Mean

• The review suggests that MSCs may be associated with modest improvements in motor outcomes in some children with CP, but responses are not uniform.
• The evidence does not establish MSCs as a proven or approved treatment for cerebral palsy.
• The findings reinforce that cerebral palsy is a heterogeneous condition, and outcomes may depend on individual patient and treatment characteristics.
• The primary value of this publication lies in guiding future clinical research, including study design, outcome selection, and patient stratification.

Systemic Lupus Erythematosus (SLE)

UC-MSCs have shown potential in treating refractory SLE. A multicenter Phase II trial involving patients with severe, treatment-resistant SLE reported a 92.5% overall survival rate. While the study documented improvements in disease activity indices, including reductions in SLEDAI scores (p < 0.001), these results require validation in larger, controlled studies. Notably, no transplantation-related adverse events were reported, though long-term safety data remain limited (Wu 2025).

Study Interpretation:
UC MSC therapy for SLE remains experimental, with early data supporting feasibility and short term safety.

Multiple autoimmune diseases (mixed populations)

Ongoing registered trials are evaluating MSC infusions across heterogeneous autoimmune conditions, including rheumatologic and systemic inflammatory diseases.

These studies commonly compare MSC therapy with placebo or standard care and emphasize:
• Immune cell subset changes
• Autoantibody levels
• Safety outcomes at short term follow up (3–6 months).

Study Interpretation:
These trials are designed to generate hypothesis level data and to inform future, disease specific studies.

Rheumatoid arthritis (RA)

Reviews published in 2025 summarize preclinical models and limited early clinical experience using perinatal tissue–derived MSCs for RA.

Available clinical data suggest acceptable short term safety, but clinical efficacy remains unproven, with few controlled trials completed to date (Alivernini 2025).

What the broader emerging research landscape shows

Safety:
Early phase trials and expanded access programs have generally reported that UCB infusions were feasible and well tolerated, with no consistent new safety concerns identified across preliminary outcomes:
Some studies have observed modest functional changes in subsets of participants; however, results have been variable and not uniform across patients or conditions. These findings are exploratory and not definitive.

What These Findings Mean

Large systematic analyses of stem cell–based trials in autoimmune diseases show that:
• Umbilical cord and placenta derived MSCs are among the most frequently used cell sources
• More than 80% of studies are Phase I–II
• Regulatory approval has not yet been established for autoimmune indications outside hematopoietic stem cell transplantation related contexts.

Key Takeaway for Parents and Clinicians:

Current Research in Autoimmune Diseases with Cord Blood and Postpartum Tissue–Derived Cell Therapies is Active but Early Stage.

Conditions Studied

• Osteoarthritis (knee and hip)
• Degenerative disc disease and back pain
• Cartilage and meniscal injuries
• Tendon and ligament injuries

Most studies explore local (intra articular or intralesional) administration of perinatal MSCs, rather than systemic infusion.

What The Researchers Are Studying

Across musculoskeletal trials, primary objectives include:
• Safety and tolerability of postpartum tissue–derived MSCs
• Feasibility of local delivery into joints or soft tissues
• Exploratory assessments of:
• Pain scores
• Functional measures (e.g., mobility, joint range of motion)
• Imaging or biomarker changes
These outcomes are exploratory and often assessed over short follow up periods (typically 3–12 months).

What Type of Cord Blood is Used

Depending on the protocol, studies have involved:
• Autologous cord blood (the child’s own stored cord blood)
• Allogeneic cord blood (sibling or unrelated donor units)
Cord blood units must meet predefined criteria for cell dose, sterility, and viability. Infusions are administered without chemotherapy or immunosuppression and are considered minimally manipulated cellular therapies under research protocols.

What Has Been Observed So Far

Safety:
Early phase studies and reviews consistently report acceptable short term safety, with most adverse events described as mild to moderate (e.g., transient injection site pain or swelling). Serious adverse events directly attributable to cells are uncommon in published trials, recognizing that sample sizes are limited.

Clinical signals:
Some trials report improvements in pain or function in subsets of participants. However, outcomes are variable, placebo effects are difficult to exclude, and methodological limitations (small size, lack of blinding, inconsistent endpoints) prevent conclusions about efficacy.

These findings are summarized in recent reviews of perinatal MSC use in musculoskeletal and inflammatory joint conditions, including rheumatoid arthritis and degenerative joint disease (Acharya 2025).